Compare · BBNX vs RMD
BBNX vs RMD
Side-by-side comparison of Beta Bionics Inc. (BBNX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.09B, about 37.3x BBNX ($888.1M).
- Over the past year, BBNX is down 18.3% and RMD is down 11.8% - RMD leads by 6.5 points.
- BBNX has been more active in the news (10 items in the past 4 weeks vs 9 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 21 for BBNX).
- Company
- Beta Bionics Inc.
- ResMed Inc.
- Price
- $16.89-2.62%
- $238.20-1.71%
- Market cap
- $888.1M
- $33.09B
- 1M return
- -21.32%
- +4.22%
- 1Y return
- -18.31%
- -11.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 10
- 9
- Recent ratings
- 21
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest BBNX
- BBNX DEADLINE: Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of Upcoming Securities Class Action Deadline
- Jefferies initiated coverage on Beta Bionics with a new price target
- BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
- SEC Form SCHEDULE 13G filed by Beta Bionics Inc.
- Barclays initiated coverage on Beta Bionics with a new price target
- SEC Form 4 filed by Beta Bionics Inc.
- Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Director Jones Christy sold $147,890 worth of shares (6,430 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 19,564 units (SEC Form 4)
- Wells Fargo initiated coverage on Beta Bionics with a new price target
- Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target